• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
TechPharmaceutical Industry
Europe

AstraZeneca to buy cell therapy biotech for up to $1 billion

By
Ashleigh Furlong
Ashleigh Furlong
and
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Ashleigh Furlong
Ashleigh Furlong
and
Bloomberg
Bloomberg
Down Arrow Button Icon
March 17, 2025, 7:50 AM ET
Pascal Soriot, chief executive officer of AstraZeneca.
Pascal Soriot, chief executive officer of AstraZeneca.Cole Burston/Bloomberg via Getty Images

AstraZeneca Plc, the UK drugmaker, agreed to buy the Belgian cell therapy developer EsoBiotec for as much as $1 billion to further boost its cancer capabilities. 

Recommended Video

AstraZeneca will pay $425 million upfront and may spend up to $575 million more in development and regulatory milestones, the companies said Monday. 

As Chief Executive Officer Pascal Soriot reaps the rewards of doubling down on the competitive market for cancer medicines with blockbusters like Tagrisso, Astra is targeting the next generation of potential treatments. 

EsoBiotec’s platform has the potential to transform cell therapy, according to Astra, by empowering the immune system to attack cancers. It uses targeted viruses to engineer immune cells directly within a person’s body and could allow treatment to be delivered in minutes rather than the current standard of several weeks. 

Astra shares were little changed in early London trading, rising less than 1%. The stock has gained almost 15% so far this year. 

Current CAR-T cell therapies require doctors to harvest cells from patients, engineer them in the laboratory and then re-infuse them into a patient. While these medicines can treat certain cancers, they are expensive and difficult to manufacture, prompting drugmakers to develop medicines that could engineer cells within the body. 

EsoBiotec in January announced the start of a trial testing its experimental therapy for multiple myeloma in collaboration with China’s Shenzhen Pregene Biopharma Co. The goal is to achieve cancer-free bone marrow without requiring chemotherapy to achieve lymphodepletion as needed in traditional CAR-T treatment.

Under the terms of the deal, EsoBiotec will become a subsidiary of Astra and maintain operations in Belgium. The transaction is expected to close in the second quarter. Prior to it, Esobiotec had only raised €22 million ($24 million).

In a separate cancer deal announced Monday, Astra agreed to license a plaform to make subcutaneous drug formulations from Alteogen Inc. It didn’t disclose financial details. 

Join us at the Fortune Workplace Innovation Summit May 19–20, 2026, in Atlanta. The next era of workplace innovation is here—and the old playbook is being rewritten. At this exclusive, high-energy event, the world’s most innovative leaders will convene to explore how AI, humanity, and strategy converge to redefine, again, the future of work. Register now.
About the Authors
By Ashleigh Furlong
See full bioRight Arrow Button Icon
By Bloomberg
See full bioRight Arrow Button Icon

Latest in Tech

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Latest in Tech

OpenAI CEO Sam Altman says Gen Z and millennials are using ChatGPT like a ‘life advisor’—but college students might be one step ahead
TechOpenAI
OpenAI CEO Sam Altman says Gen Z and millennials are using ChatGPT like a ‘life advisor’—but college students might be one step ahead
By Sydney LakeMay 10, 2026
2 hours ago
Torsten Slok, wearing a suit, speaks on a stage with a gold and black background.
AILabor
‘The gains will be substantial’: The AI shock is looking a lot like the China shock, and a top economist says that’s actually good news
By Sasha RogelbergMay 10, 2026
4 hours ago
Young man working on laptop with headphones in modern coffeeshop
Future of Workskills gap
AI generated identical résumés for a man and a woman: Hers was more likely to be labeled ‘weak,’ while his got a 97% approval rating
By Eleanor PringleMay 10, 2026
6 hours ago
UFO files show Buzz Aldrin saw a ‘sizeable’ object close to the moon and a ‘fairly bright light source’ that the Apollo 11 crew felt could be a laser
Innovationspace
UFO files show Buzz Aldrin saw a ‘sizeable’ object close to the moon and a ‘fairly bright light source’ that the Apollo 11 crew felt could be a laser
By Seung Min Kim, Collin Binkley and The Associated PressMay 9, 2026
24 hours ago
joaquin
Commentary250 Years of Innovation
Johnson & Johnson CEO: America’s innovation advantage starts with health 
By Joaquin DuatoMay 9, 2026
1 day ago
Qualcomm’s CEO is working with ‘pretty much all’ major AI players on top-secret devices—and powering OpenAI’s first push into hardware
AIQualcomm
Qualcomm’s CEO is working with ‘pretty much all’ major AI players on top-secret devices—and powering OpenAI’s first push into hardware
By Eva RoytburgMay 9, 2026
1 day ago

Most Popular

'Employers are increasingly turning to degree and GPA' in hiring: Recruiters retreat from ‘talent is everywhere,’ double down on top colleges
Future of Work
'Employers are increasingly turning to degree and GPA' in hiring: Recruiters retreat from ‘talent is everywhere,’ double down on top colleges
By Jake AngeloMay 9, 2026
1 day ago
Ted Cruz says the quiet part out loud: Trump accounts are Social Security personal accounts as GOP senator reveals 'dirty little secret'
Politics
Ted Cruz says the quiet part out loud: Trump accounts are Social Security personal accounts as GOP senator reveals 'dirty little secret'
By Jason MaMay 9, 2026
21 hours ago
Red flag test: former CEO explains why he rejects job candidates who say they can start right away
Success
Red flag test: former CEO explains why he rejects job candidates who say they can start right away
By Orianna Rosa RoyleMay 9, 2026
1 day ago
Companies are abandoning 'peanut butter' raises as pay-for-performance takes over the workplace in the AI era
Future of Work
Companies are abandoning 'peanut butter' raises as pay-for-performance takes over the workplace in the AI era
By Marco Quiroz-GutierrezMay 9, 2026
1 day ago
You're probably safe from the Hantavirus outbreak, but here's what you absolutely must not do, experts say
Politics
You're probably safe from the Hantavirus outbreak, but here's what you absolutely must not do, experts say
By Catherina GioinoMay 8, 2026
2 days ago
The federal government must issue more debt than it expected as cash flow weakens, and 'the bond market is shouting'
Investing
The federal government must issue more debt than it expected as cash flow weakens, and 'the bond market is shouting'
By Jason MaMay 9, 2026
15 hours ago